KalVista reports preliminary Q4 EKTERLY revenue of ~$35M, full-year ~$49M; 1,318 patient start forms

KalVista Pharmaceuticals, Inc.

2025-FY EPS reported -$2.03 revenue$49,078,000

Preliminary unaudited global net product revenue: ~$35M for Q4 2025, ~$49M for full year 2025.
1,318 patient start forms and 580 unique prescribers activated in the US through Dec 31, 2025.
Prescription refills surpassed initial prescriptions as the primary revenue driver in Q4.
Entered Latin America partnership with Multicare Pharma for Brazil, Argentina, Colombia, Mexico.
Expect to file NDA for pediatric HAE patients (ages 2-11) in Q3 2026; US launch anticipated in 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.